Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
195
-
Total 13F shares, excl. options
-
107M
-
Shares change
-
-593K
-
Total reported value, excl. options
-
$3.15B
-
Value change
-
-$754K
-
Put/Call ratio
-
0.71
-
Number of buys
-
108
-
Number of sells
-
-76
-
Price
-
$29.51
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q2 2023
225 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q2 2023.
Denali Therapeutics Inc. - Common Stock (DNLI) has 195 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 145M outstanding shares and own 73.46% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (14.8M shares), VANGUARD GROUP INC (10.2M shares), BlackRock Inc. (10.1M shares), WELLINGTON MANAGEMENT GROUP LLP (7.04M shares), Temasek Holdings (Private) Ltd (6.9M shares), Crestline Management, LP (6.11M shares), STATE STREET CORP (4.47M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.45M shares), Capital Research Global Investors (2.84M shares), and Flagship Pioneering Inc. (2.62M shares).
This table shows the top 195 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.